New PET tracer aims to spot hidden cancers

NCT ID NCT07602569

Recruiting now Diagnosis Sponsor: Affiliated Cancer Hospital & Institute of Guangzhou Medical University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new radioactive tracer called 18F-FGln, which targets glutamine—a nutrient that cancer cells need to grow. Researchers want to see if PET/CT scans using this tracer can more accurately detect and stage various cancers, especially those that are hard to see with standard scans. The study will involve 110 people with suspected or confirmed cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-FGln (a radioactive tracer for PET imaging)
What this could lead to: If successful, this could provide a more accurate way to diagnose and stage certain cancers, especially where current scans may miss or misread tumors.
What could go wrong: This is an early-stage study with only 110 participants, so results may not apply to all cancers. The tracer's effectiveness compared to standard methods is still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER (WITH OR WITHOUT METASTASIS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER (WITH OR WITHOUT METASTASIS)

Contacts and locations

Locations

Affiliated Cancer Hospital & Institute of Guangzhou Medical University
RECRUITING

Guangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.